Larner College of Medicine, University of Vermont, Burlington, VT.
Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA.
Crit Care Med. 2021 May 1;49(5):e500-e511. doi: 10.1097/CCM.0000000000004917.
Hypercoagulability may be a key mechanism for acute organ injury and death in patients with severe coronavirus disease 2019, but the relationship between elevated plasma levels of d-dimer, a biomarker of coagulation activation, and mortality has not been rigorously studied. We examined the independent association between d-dimer and death in critically ill patients with coronavirus disease 2019.
Multicenter cohort study.
ICUs at 68 hospitals across the United States.
Critically ill adults with coronavirus disease 2019 admitted to ICUs between March 4, 2020, and May 25, 2020, with a measured d-dimer concentration on ICU day 1 or 2.
None.
The primary exposure was the highest normalized d-dimer level (assessed in four categories: < 2×, 2-3.9×, 4-7.9×, and ≥ 8× the upper limit of normal) on ICU day 1 or 2. The primary endpoint was 28-day mortality. Multivariable logistic regression was used to adjust for confounders. Among 3,418 patients (63.1% male; median age 62 yr [interquartile range, 52-71 yr]), 3,352 (93.6%) had a d-dimer concentration above the upper limit of normal. A total of 1,180 patients (34.5%) died within 28 days. Patients in the highest compared with lowest d-dimer category had a 3.11-fold higher odds of death (95% CI, 2.56-3.77) in univariate analyses, decreasing to a 1.81-fold increased odds of death (95% CI, 1.43-2.28) after multivariable adjustment for demographics, comorbidities, and illness severity. Further adjustment for therapeutic anticoagulation did not meaningfully attenuate this relationship (odds ratio, 1.73; 95% CI, 1.36-2.19).
In a large multicenter cohort study of critically ill patients with coronavirus disease 2019, higher d-dimer levels were independently associated with a greater risk of death.
高凝状态可能是导致严重 2019 冠状病毒病(COVID-19)患者急性器官损伤和死亡的关键机制,但血浆 D-二聚体水平升高(凝血激活的标志物)与死亡率之间的关系尚未得到严格研究。我们研究了 D-二聚体与 COVID-19 重症患者死亡之间的独立关系。
多中心队列研究。
美国 68 家医院的 ICU。
2020 年 3 月 4 日至 2020 年 5 月 25 日期间入住 ICU 的 COVID-19 重症成年患者,在 ICU 第 1 或第 2 天测量 D-二聚体浓度。
无。
主要暴露因素是 ICU 第 1 或第 2 天最高标准化 D-二聚体水平(分为 4 类:<2×、2-3.9×、4-7.9×和≥8×正常值上限)。主要终点是 28 天死亡率。多变量逻辑回归用于调整混杂因素。在 3418 例患者(63.1%为男性;中位年龄 62 岁[四分位距 52-71 岁])中,3352 例(93.6%)的 D-二聚体浓度高于正常值上限。共有 1180 例(34.5%)患者在 28 天内死亡。在单因素分析中,最高与最低 D-二聚体类别相比,死亡风险高 3.11 倍(95%CI,2.56-3.77),在调整人口统计学、合并症和疾病严重程度后的多变量分析中,死亡风险增加 1.81 倍(95%CI,1.43-2.28)。进一步调整治疗性抗凝治疗并没有显著减弱这种关系(比值比,1.73;95%CI,1.36-2.19)。
在一项针对 COVID-19 重症患者的大型多中心队列研究中,较高的 D-二聚体水平与死亡风险增加独立相关。